Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + Bortezomib + Dexamethasone in Relapsed Multiple Myeloma
NCT02605356Phase 2Withdrawn
- Sponsor
- Bayer
- Start
- Oct 2016
- Primary completion
- Nov 2019
- Modality
- Radiopharmaceutical
- Countries
- 11
01
Overview
A Phase 2 trial of radium-223 dichloride in multiple myeloma (MM), sponsored by Bayer. Planned start Oct 2016; status: withdrawn.
02
Drugs
radium-223 dichloride
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02605356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605356.